Phaseline

Companies › SUNHO(China)BioPharmaceutical

SUNHO(China)BioPharmaceutical: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IAH0968
HER2-targeting biologic (mechanism unclear from registry)
–Phase 2Stomach NeoplasmsJul 2028
IAP0971
PD-L1 inhibitor
–Phase 1Advanced Malignant Tumors; Advanced Malignant NeoplasmMar 2027
IBD0333–Phase 1MTDDec 2029
IBB0979
unclear - immunotherapy agent
–Phase 1Advanced Malignant Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05991583IBB0979Phase 1Advanced Malignant TumorsOncologyNov 2025
NCT06223841IAP0971Phase 1Advanced Malignant TumorsOncologyMar 2027
NCT06504732IAH0968Phase 2Stomach NeoplasmsOncologyJul 2028
NCT06581419IAP0971Phase 1Advanced Malignant NeoplasmOncologyAug 2029
NCT06292208IBD0333Phase 1MTDOtherDec 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

GI Innovation OBI Pharma Ranok Therapeutics (Hangzhou) Shanghai EpimAb Biotherapeutics Tyra Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.